This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic Project for...
3 min
12 Mar, 2024
ROVI achieved operating revenue growth of 1% in the first post-pandemic year
4 min
27 Feb, 2024
ROVI reports operating revenue growth of 3% for the first nine months of the first post-pandemic year
5 min
08 Nov, 2023
For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world...
3 min
04 Aug, 2023
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of...
1 min
28 Jul, 2023
ROVI achieved stable total revenue of 381.0 million euros in the first post-pandemic half year
4 min
26 Jul, 2023
ROVI reached 201.9 million euros of revenue in the first post-pandemic quarter
3 min
10 May, 2023
The objective of the new three-monthly formulation is to reach bioequivalence in the plasma levels of letrozole in...
6 min
25 Apr, 2023
The objective is to help improve society’s mental health and take advantage of the opportunities the new technologies...
3 min
12 Apr, 2023